We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
With no glaring legal discrepancies in a lower court ruling that sustained the validity of Eli Lilly’s Zyprexa patent, generic firms will have to wait five years before bringing their versions of the schizophrenia treatment drug to market, a federal appeals court has ruled.
Reliant Pharmaceuticals has filed a lawsuit against Par Pharmaceutical in response to Par’s plan to market propafenone HCl capsules, a generic version of Rythmol SR extended-release capsules.
Ortho-McNeil Pharmaceutical has filed a patent infringement lawsuit to stop Barr Laboratories’ move to offer a generic version of the epilepsy and migraine drug, Topamax.
Biovail has filed a lawsuit against the FDA and is asking a federal court to reverse an agency decision approving the marketing of a generic version of its antidepressant drug, Wellbutrin XL.
Pfizer’s inhalable insulin product Exubera will stay on the market while a court considers whether the company infringed on Novo Nordisk’s patents, a U.S. district judge ruled.
Armed with several production and method-of-use patents covering its cancer drug Thalomid, Celgene is preparing a legal challenge to head off Barr Laboratories’ move to market thalidomide, a generic version of the drug, company executives said.
The U.S. Court of Appeals for the Federal Circuit has granted Savient Pharmaceutical’s last-minute request asking the court to prevent sales of generic Oxandrin from going forward.
The U.S. District Court for the District of New Jersey has vacated an earlier ruling that blocked generic producers Sandoz Pharmaceuticals and Upsher-Smith Laboratories from marketing their newly approved oxandrolone product, a generic version of Savient Pharmaceutical’s Oxandrin.
Merck denounced a plan by the government of Thailand to offer its poorer citizens access to a relatively inexpensive generic version of its anti-retroviral drug, efavirenz, used to combat HIV/AIDS.
The U.S. District Court for the Southern District did not “abuse its discretion” in granting a preliminary injunction against Apotex blocking further sales of its generic Plavix (clopidogrel bisulfate) pending the outcome of the patent challenge, a federal appeals court determined.